|
|
name  click to compare prices |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
| shareholder | country | % | source |
|
year | business source |
| 2006 | Amgen is the world's tenth-largest pharmaceutical group. | Les Echos |
| 2004 | Largest biotechnology group in the world. | Les Echos |
|
| year name | photo position; compensation source |
| 2006Morrow, Georges |  Vice-president; salary: 2.69 million US$; stock-options: 6.92 million US$; Company |
| 2005Danula, Richard D | Chief Financial Officer; salary: 1.98 million US$; stock-options: 3.46 million US$; Company |
| 2005Sharer, Kevin W | Chief Executive Officer; salary: 5.89 million US$; stock-options: 27.87 million US$; Company |
|
| year | employees <> | social impact : country source |
| 2007 | -2600 | Internal restructuring: Amgen is cutting 2600 jobs, 14% of its payroll, because lower sales of two blockbuster drugs.: United States of America | Les Echos |
|
| year | employees <> | social impact : country source |
|
| year | financial misdemeanor | sales | income | | buyback | source |
| 2005 |
| 12.43 | 4.02 | | | billion US$ | Company |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | | | | Canadian Press |
| 2004 |
| 10.55 | 3.15 | | | billion US$ | Enjeux Les Echos |
| 2003 |
| 8.36 | -2.54 | | | billion US$ | Company |
| 2002 |
| 5.52 | -1.66 | | | billion US$ | Company |
| 2001 |
| 4.02 | 1.12 | | | billion US$ | Company |
| 2000 |
| 3.63 | 1.14 | | | billion US$ | Company |
| 1999 |
| 3.34 | 1.1 | | | billion US$ | Company |
| 1999 |
| | | | 2 | billion US$ | SmartMoney |
| 1998 |
| 2.72 | 0.86 | | | billion US$ | Company |
| 1998 |
| | | | 1 | billion US$ | SmartMoney |
|
| year | financial misdemeanor | sales | income | assets | buyback | source |
|
| year | purpose : intermediary/lobby : institution source |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate  translate | Washington Post |
| 1998 | Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 74 thousand US$ : US President, Congress, Senate translate | Center for Responsive Politics |
|
| year | purpose : intermediary/lobby : institution source |
|
|
|
Contribute
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
